Core Insights - Pinnacle Food (PFAI) is leveraging a cross-continental innovation collaboration model to establish a comprehensive biomanufacturing system that spans "technology research and development, equipment manufacturing, and industrial application" [1] - The company’s core competitiveness lies in its precise control over key biomanufacturing processes, integrating technological innovation and resource consolidation [1] Group 1: Technological Innovations - PFAI focuses on the precise development of specialized strains and specific enzymes, which is central to its technological strategy [1] - The company has integrated CRISPR gene editing technology with AI algorithms to create an intelligent strain design platform, enhancing the efficiency of microbial metabolic pathway regulation [1] - This "data-driven + mechanism innovation" research model significantly shortens the strain optimization cycle, improving the conversion efficiency from laboratory to industrialization [1] Group 2: Strategic Collaborations - PFAI has signed a cooperation agreement with Bioboost Synbio Consulting Inc., which will provide end-to-end laboratory construction services, enhancing the efficiency and compliance of strain research and biomanufacturing [2] - The collaboration with Bioboost will facilitate the establishment of a high-standard biomanufacturing and testing laboratory in the Hong Kong-Shenzhen Innovation and Technology Park [2] Group 3: Modular Equipment Development - The development and manufacturing of modular intelligent equipment are key to overcoming industrialization bottlenecks in biomanufacturing [3] - PFAI's functional plant smart cultivation module allows for flexible production through precise environmental control and standardized biological cultivation systems [3] - The production of this core equipment is based in China, leveraging the country's complete supply chain capabilities, with initial products already shipped to global markets [3] Group 4: Cross-Border Collaboration - PFAI's establishment in the Hong Kong-Shenzhen Innovation and Technology Park enhances its biomanufacturing advantages through a dual-channel approach that connects local and mainland research resources [4] - The company benefits from Hong Kong's free port status and cross-border data flow pilot policies, enabling efficient collaboration and compliance in global research data sharing [4] - The upcoming implementation of the China-Canada trade agreement in early 2026 is expected to provide policy benefits, reducing costs for cross-border research equipment and results [4] Group 5: Market Positioning - As the global biomanufacturing industry approaches a scale of $4 trillion, PFAI exemplifies how the integration of technological innovation, cross-border collaboration, and strategic partnerships can overcome industry bottlenecks [5] - The company’s comprehensive capabilities in "strain design, equipment manufacturing, and industrialization" position it to drive significant growth and establish the Guangdong-Hong Kong-Macao Greater Bay Area as a core hub for global biomanufacturing innovation [5] - Future advancements in non-grain biomass utilization and smart bioreactors, along with more cross-border projects, are expected to solidify PFAI's position in the biomanufacturing sector [5]

Core Insights - The biomanufacturing sector is gaining momentum with strong policy support and technological advancements, positioning it as a key future industry in China [1][2] - The market size of China's biomanufacturing industry is projected to reach approximately 1.8 trillion yuan by 2030, with significant contributions from food additives and biopharmaceuticals [1][2] Industry Developments - The Ministry of Industry and Information Technology has reported that during the 14th Five-Year Plan, China's biomanufacturing industry is expected to expand steadily, reaching a total scale of 1.1 trillion yuan, with bioproducts accounting for over 70% of global production [1] - The focus of the 14th Five-Year Plan is on the industrialization of technology, emphasizing pilot testing, process scaling, and demonstration line construction [2] Company Initiatives - Ruipu Biotech is investing 680 million yuan in a large-scale microbial protein industrialization demonstration project, aiming for trial production by Q4 2026 [3] - Fuxiang Pharmaceutical is leveraging its expertise in high-end antibiotic fermentation to enhance its microbial protein project, focusing on domestic and international expansion [4] - Yikela Biotech is targeting high-value aquatic feed proteins through a collaboration with Fudan University, aiming to reduce reliance on imported fishmeal [5] Technological Advancements - Synthetic biology is identified as a core technology driving low-carbon production and increased labor productivity across various sectors, including healthcare and industrial manufacturing [2] - The integration of AI with synthetic biology is expected to shift the competitive landscape from single-point breakthroughs to platform-based competition, enhancing R&D efficiency [7] Market Trends - The most promising sub-sectors in biomanufacturing during the 14th Five-Year Plan include high-value biomanufactured products in healthcare, bio-based materials, and service-oriented platforms [6] - The industry is anticipated to experience differentiation and improved quality as companies focus on scalable processes, cost control, and clear downstream applications [2][6]

作为未来产业之一，生物制造赛道近期多点开花、动能充沛。政策层面持续加码，上海市近期印发行动 方案，将生物制造纳入积极引导的新兴产业领域，确立其战略优先级；企业端积极发力，富祥药业通过 成立跨国合资公司推进微生物蛋白全球化布局；科研前沿同步突破，"合成高等生物"先导项目启动，AI 驱动下的生命科学创新持续深化，多方协同发力激活万亿产业新潜力。 ● 本报记者 傅苏颖 万亿赛道根基渐牢 近年来，政策高度聚焦产业化落地与技术突破，形成多层次支撑体系，促进我国生物制造产业蓬勃发 展。 工信部此前披露，"十四五"期间，我国生物制造产业规模稳步扩大，总规模达1.1万亿元，生物发酵产 品产量占全球70%以上。其中食品及添加剂、生物制药等细分领域年产值超4000亿元，推动生物制造成 为新的经济增长点。易凯资本预测，到2030年，中国生物制造市场规模将会接近1.8万亿元。 长城证券化工新材料首席分析师肖亚平在接受中国证券报记者采访时表示，合成生物学技术作为生物制 造的核心支撑，可推动产业实现低碳生产、提升劳动生产率，其成果广泛应用于医疗健康、能源开发、 环境保护、工业制造等多个领域，为解决人类面临的各类发展挑战提供创新解决方案， ...

近年来，合成生物学技术迭代更新迅猛，与生物医药产业深度融合，在 药物研发、疾病诊疗和绿色可 持续生产 等关键领域展现出巨大潜力与广阔市场空间。在疾病诊断方面，合成生物学为早期、精确诊 断提供了创新思路与技术支撑；在疾病治疗方面，基于合成生物学原理的细胞疗法、细菌疗法、新型疫 苗和生物医学材料等前沿成果不断涌现，为患者带来新希望。据相关数据显示，2023年全球合成生物学 市场规模已突破 170亿美元 ，其中医疗健康领域约 64亿美元 ，占比近 40% 。未来合成生物学在医疗健 康领域的应用规模有望持续攀升，预计到2028年将达到 133亿美元 。随着基因编辑、高通量测序、生物 信息学和人工智能等技术的不断进步，合成生物学在医药领域的应用场景将不断拓展，为医药产业的转 型升级提供强大动力。 2025第二届合成生物制造创新发展大会 将于 2025年5月22-23日 在 上海浦东喜来登由由大酒店 盛大启 幕。本次大会以" 合成新'基'遇，智造赢未来 "为主题，邀请全球生物制造领域的专家、企业家和科研 机构，聚焦合成生物技术在 医药、食品、化妆品、新材料、AI方向 的应用，共同探讨生物制造技术的 发展趋势、市场机遇与挑 ...